Fulltext

Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring

Santschi, Valérie ; Wuerzner, Grégoire ; Schneider, Marie-Paule ; Bugnon, Olivier ; Burnier, Michel

In: European Journal of Clinical Pharmacology, 2007, vol. 63, no. 12, p. 1179-1184

Add to personal list
    Title
    • Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring
    Author
    • Santschi, Valérie. Policlinique Médicale Universitaire, Lausanne, Switzerland
    • Wuerzner, Grégoire. Division of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 17, 1011, Lausanne, Switzerland
    • Schneider, Marie-Paule. Policlinique Médicale Universitaire, Lausanne, Switzerland
    • Bugnon, Olivier. Policlinique Médicale Universitaire, Lausanne, Switzerland
    • Burnier, Michel. Policlinique Médicale Universitaire, Lausanne, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • European Journal of Clinical Pharmacology, 2007, vol. 63, no. 12, p. 1179-1184. Springer-Verlag
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:314989
    Summary
    Objective: The goal of this study was to evaluate clinically the acceptability of the IDAS II (Intelligent Drug Administration System), a new electronic device that enables drug adherence monitoring. Methods: IDAS II was compared to another electronic monitor, the Medication Event Monitoring System (MEMS) in a randomised two-way cross-over study involving 24 hypertensive patients treated with irbesartan. Patients used each device for 2months. The main parameter of evaluation was the patients' opinion on both devices. Rates of adherence and blood pressure were also assessed. Results: Most patients considered both devices to be reliable reminders (IDAS II: 75%;MEMS: 84%, p = ns). Ten patients (42%) preferred the MEMS, while 11 (46%) preferred the IDAS II; three (12%) expressed no preference. Patients found the MEMS device easier to use than the IDAS device (p < 0.001) but appreciated the IDAS blister packs better than the MEMS bulk packaging (p < 0.01). Over the 4-month period, the median "taking adherence” was excellent (99.2%) and comparable with both devices. However, the regularity of drug intake timing was higher with the IDAS II (p < 0.01). Conclusion: IDAS II, a new electronic device enabling drug adherence monitoring without reconditioning of the drugs appears to be a well-accepted device. Overall, practicability and acceptability of the IDAS II and the MEMS device were similar. Thus, IDAS II could be a useful tool for the management of long-term therapies